Pfizer Inc. (PFE)
Pfizer Offers High Yield And Capital Appreciation Opportunities (Technical Analysis)
Pfizer surged 15% last week on positive news, including a direct-to-consumer deal and a three-year tariff reprieve. PFE offers a high 6.28% yield, with a forward PE of 8.87, and its dividend is considered safe by Seeking Alpha. Technical analysis shows PFE above its 30-week EMA, with bullish short- and long-term momentum and strong buying volume from institutional investors.
Eli Lilly Stock Soars on Trump Tariff Hopes and Pfizer Deal
After tanking in early August, the world's most valuable pharmaceutical stock has roared back with a vengeance. That firm is Eli Lilly and Company NYSE: LLY, the maker of the wildly popular weight loss and diabetes drugs Zepbound and Mounjaro.
Will Pfizer (PFE) Beat Estimates Again in Its Next Earnings Report?
Pfizer (PFE) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Pfizer Inc. (NYSE: PFE) Price Prediction and Forecast 2025-2030 (October 2025)
Shares of Pfizer ( NYSE: PFE ) gained 10.02% over the past month after gaining 4.50% the month prior.
Is PFE Stock a Buy After 14% Rise Post Drug Pricing Deal With Trump?
Pfizer surges 14% after landmark Trump deal slashing drug prices while boosting U.S. investments.
The drug price deal between Pfizer and the Trump administration was built on down-to-the-wire team negotiations, building on a relationship between CEO Albert Bourla and President Trump
Down-to-the wire team negotiations capped a long dance between President Trump and CEO Albert Bourla.
Heard on the Street: Pfizer's accord on price cuts with President Trump clears a cloud over the whole pharma industry
The company's accord with the president clears a cloud over the whole sector.
Top 3 Dividend Achievers for October: High Yields, Growth Ahead
These stocks are attractive investments due to their proven models, stable cash flow, and ability to sustain capital returns, which may also lead to share price increases and capital gains.
Pfizer's Art Of The Deal
President Trump and Pfizer announced a deal to cut drug pricing yeseterday. And it looks like the pharmaceutical giant got the better end of it.
This 6.75%-Yielding Dividend Stock Can Gain 33%
Pfizer (NYSE:PFE) shares are finally starting to attract attention after gaining close to 7% in a single trading session on news that it's reached a pricing deal with the Trump administration.
Pfizer Drug-Pricing Deal: More Upside For PFE Stock?
Pfizer stock (NYSE: PFE) offers a compelling investment opportunity at its current price of around $25, supported by attractive valuations and recent policy changes that may present further upside potential.
Trump's pharmaceutical tariff threat loses bite after Pfizer deal reassures drugmakers
President Donald Trump's long-awaited threat to impose pharmaceutical tariffs may not pose as much of a challenge as drugmakers once feared, following his new drug-pricing deal with Pfizer. Trump's agreement with Pfizer included a three-year exemption from pharmaceutical-specific tariffs, so long as the firm further invests in domestic manufacturing.
